About JIGH Advisors and Fellows

Advisors

Advisors

Advisors Harvey V. Fineberg, M.D., Ph.D.

Advisor

Harvey V. Fineberg, MD, PhD

President, Institute of Medicine

Dr. Fineberg served as dean of the faculty of Public Health at Harvard University for 13 years before his appointment to provost of the university from 1997 to 2001. His academic career has been dedicated to public health policy and decision making, and he has conducted research on policy making and implementation, the evaluation of medical technology and vaccines, as well as the spread of medical innovations.

Dr. Fineberg served as the president of the Society for Medical Decision Making, and also worked as a WHO consultant. He was appointed president of the Institute of Medicine and chaired several panels focusing on the development of problem-solving strategies to address a variety of public health policy issues, from AIDS to medical innovations.

He also served as a member of the Public Health Council of Massachusetts (1976–1979), chairman of the Health Care Technology Section of the National Center for Health Services Research (1982–1985) and as president of the Association of Schools of Public Health.

He obtained his Bachelor’s degree and PhD at Harvard University.

Advisors Julio Frenk, Dean フリオ・フランク

Advisor

Julio Frenk, Dean

Dean of the Faculty, Graduate School of Public Health, Harvard University
T&G Angelopoulos Professor of Public Health and International Development, Harvard School of Public Health and Harvard Kennedy School, Harvard University

On January 1, 2009, Dr. Frenk was appointed both as the dean of the faculty of Public Health, Harvard University and the T&G Angelopoulos professor in the fields of Public Health and International Development.

A leading figure in global health, Dr. Frenk served as the minister of health in Mexico from 2000 to 2006. In this role, he aimed to tackle social inequality through a series of reforms to the national health system. One of his landmark achievements was the introduction of Seguro Popular, a program of comprehensive national health insurance, which gave tens of millions of previously uninsured Mexicans access to health care.

Dr. Frenk served as the founding-director general of the National Institute of Public Health of Mexico, an eminent health education and research institute for developing countries. In 1998, he was appointed as the executive director of the Evidence and Information for Policy unit at WHO, the first to be committed to establishing a scientific base for the improvement of results in health policy making.

More recently, Dr. Frenk became a senior fellow of the Bill & Melinda Gates Foundation’s Global Health Program, and also served as the head of the Carso Health Institute in Mexico City. He is the current chair of the board of the Institute for Health Metrics and Evaluation at the University of Washington.

Dr. Frenk obtained his Bachelor’s degree from the National University of Mexico. He holds both a Master’s degree in Public Health and a joint doctorate in Medical Care Organization and Sociology from the University of Michigan.

He was presented with the Clinton Global Citizen Award in September 2008 for his role in changing practitioners’ and policy makers’ attitudes to health.

Advisors Dr. Tadataka Yamada

Advisor

Dr. Tadataka Yamada

Takeda Pharmaceutical Co. Ltd.
Director, Chief Medical and Scientific Officer, Executive Vice President,

Dr. Yamada is responsible for all R&D activities at Takeda Pharmaceutical Company and chairs the Corporate Management Operating Committee that manages licensing contracts for R&D projects and business development. He is the former president of the Bill & Melinda Gates Foundation Global Health Program, where he oversaw grants of more than USD 9 billion for the application of technologies to target major health issues in developing countries, including tuberculosis, HIV, malaria and other infectious diseases, malnutrition, and maternal and child health. Dr. Yamada has also served as a member of the Board of Directors and chair of R&D at GlaxoSmithKline.

Advisors Kenichi Matsumoto 松本謙一

Advisor

Kenichi Matsumoto

CEO, Sakura Global Holding Co. Ltd.

Mr. Matsumoto is CEO at Sakura Global Holding Co. Ltd, a manufacturer of high-quality medical devices and technologies. He also serves as chairman for the non-profit organization, Overseas Medical Equipment Technical Assistants (OMETA). In recognition of his contribution to public health and medicine, he received the Governor of Tokyo Award for Distinguished Service in Public Health and the Minister of Health and Welfare Award for Distinguished Service in Pharmaceutical Affairs.

Advisors Makoto Aoki 青木眞

Advisor

Makoto Aoki

Infectious diseases consultant

Dr. Aoki is an infectious diseases consultant and a senior member of the American College of Physicians who provides medical education to up-and-coming physicians at hospitals across Japan. In this role, he educates medical students and young doctors in the treatment of infectious diseases, and promotes the proper use of antibiotics and best practice for managing hospital infection. In 2012 Nikkei Medical Journal listed Dr. Aoki as a leader in the advancement of medicine and medical care in Japan.

Advisors Dairiku Hozumi 穂積大陸

Advisor

Dairiku Hozumi

Unit Leader for the Improvement of Health Systems/PATH

Dr. Hozumi has served as a senior advisor to assess the effect of monitoring and evaluating international development projects by independent administrative institutions. From 2000 to 2006 he was a leading advisor on population investigation for Malawan and Zambian health institutions that received financial assistance from JICA for their management. In collaboration with other multi-national teams, he successfully completed his investigation into health service resources in the public-private sector, which contributed to the preliminary health services development plans of both countries.

Prior to his work in Africa, Dr. Hozumi was appointed as a research fellow in the Takemi Program in International Health at the Harvard School of Public Health. Later, he lectured for 5 years about health policy evaluation of community-based information systems.

Dr. Hozumi was previously appointed as a senior technical advisor for health system policy at PATH’s Immunization Solutions Global Program in September 2007 . He has worked as a senior advisor for health system policy as part of the Maternal and Child Health and Nutrition Global Program at PATH since July 2009.

He is currently a member of a working group for health prioritization at the World Development Center, and is also involved in a working group for best practice and innovation.

He holds an MD from Juntendo University, and a Master’s degree in Public Health from the University of California, Berkeley. In 2007, he completed the MIT Sloan Fellows Program in Innovation and Global Leadership. He also obtained a MBA from MIT.

Advisors Zentaro Kamei 亀井善太郎

Advisor

Zentaro Kamei

Director/Researcher, The Tokyo Foundation Advisor, Mizuho Research Institute Board Member, Asian Education and Friendship Association (AEFA)

Mr. Kamei holds a B.A from the Faculty of Economics at Keio University, held positions at the Industrial Bank of Japan, Limited (present, Mizuho Bank), Boston Consulting Group, and as a member of the House of Representatives before landing his current position. During this time, he was appointed as a lecturer at the Graduate School of Economics, Faculty of Economics at Kobe University. In private sector, he was in charge of conducting industrial surveys, M&A/corporate reorganization, organizational reforms, portfolio reform, and research on developmental reform. As a member of the House of Representatives, he worked on issuing policy statements by the bi-partisans on the reformation of the social security system, He also engages in leaders development who will be responsible for local regeneration around Japan. His research includes how the corporate organizations could utilize their comparative advantages in promoting conflict resolutions for public policy issues, in addition to policy making in Japan’s Economic and Fiscal Policy, Social Security Policy, and Science and Technology Policy.